United Therapeutics Corporation Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax
United Therapeutics Corporation (UTHR) reported Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax of -$5.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax · last filed 2026-02-25
- United Therapeutics Corporation other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2025 was -$5.00M.
- United Therapeutics Corporation other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2024 was -$5.50M.
- United Therapeutics Corporation other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2023 was -$2.00M, a 110.15% decline from fiscal 2022.
- United Therapeutics Corporation other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2022 was $19.70M, a 239.66% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax 12 month |
|---|---|
| 2025-12-31 | -$5.00M 10-K · filed 2026-02-25 |
| 2024-12-31 | -$5.50M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$2.00M 10-K · filed 2026-02-25 |
| 2022-12-31 | $19.70M 10-K · filed 2025-02-26 |
| 2021-12-31 | $5.80M 10-K · filed 2024-02-21 |
| 2020-12-31 | -$8.40M 10-K · filed 2023-02-22 |
| 2019-12-31 | -$12.90M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |